Effect of finasteride particle size reduction on its pharmacokinetic, tissue distribution and cellular permeation

Tarek A. Ahmed and Ahmed M. Al-Abd

ABSTRACT

Finasteride (FSD), a specific competitive inhibitor of the steroid type-II 5α-reductase enzyme, is used in treatment of benign prostate hyperplasia (BPH) and male pattern baldness. The drug is of limited solubility that affect its dissolution and bioavailability. The aim was to study the effect of FSD particle size reduction on the pharmacokinetic, tissue distribution and cellular permeation. An optimized drug micro- and nano-particles were developed, characterized, administered to group of rats, and systemic pharmacokinetic and tissue distribution within target and not-target organs were determined using near-infrared (NIR) spectroscopy technique. Moreover, the cellular permeation of the prepared formulations through normal prostate epithelial cells was assessed and compared to pure FSD. The developed micro- and nano-particles were of 930 and 645 nm, respectively. Plasma maximum drug levels (C_{max}) and overall exposure (AUC) of both formulations were not significantly higher than unformulated drug. However, micronized FSD achieved significant higher concentration within the target tissue (prostate) within the current study compared to pure drug and nano-sized formulation as well. Yet, this is explained by the higher sequestration ability of spleen tissue to the nano-sized formula compared to micro-sized FSD. At the cellular level, permeation of nano-sized FSD through prostate epithelial cells was superior to the unformulated FSD as well as the micro-sized drug formulation. FSD particle size reduction significantly influences its cellular permeation and to a lesser extend affect its systemic pharmacokinetics and tissue distribution after oral administration.

Introduction

Size reduction is a process of decreasing the large or coarse solid drug particles into small or fine unit masses. This process represents a potentially useful way for enhancing the bioavailability of hydrophobic drugs especially when particles in the nano-size range have been developed (Wang et al., 2013). Improving drug bioavailability due to size reduction is attributed to the increase in the drug surface area, solubility and dissolution rate (Jinno et al., 2006; Jungmann & Müller, 2008; Willmann et al., 2010). Spray and freeze drying, anti-solvent precipitation, crystallization, supercritical fluid technology, high pressure homogenization, ball milling, jet milling, crystal engineering and cryogenic spray process are techniques commonly employed to achieve size reduction (Rogers et al., 2001; Blagden et al., 2007; Sutradhar et al., 2013; Wang et al., 2013; Hao et al., 2015). The bioavailability and therapeutic activity of wide variety of drugs have been successfully augmented following size reduction of these drug particles (Van Eerdenbrugh et al., 2008; Pande & Abhale, 2013; Wang et al., 2013).

Drug pharmacokinetic inspects the change in body drug concentrations with respect to time as a function of absorption and disposition. The later represents a combination of distribution and elimination (Maureen Dale & Rang, 2012). Following absorption, the administered drug is distributed reversibly to different body tissues and organs including those responsible for the elimination, such as the liver and the kidney, which results in a marked decrease in blood drug concentration. For poorly soluble drugs that are administered orally, there is always a low concentration gradient between the amount of drug at the absorption site and blood vessels which leading to inadequate drug absorption and distribution. Increasing both the drug solubility and dissolution rate via particle size reduction is considered as a promising approach in improving the drug pharmacokinetic and therapeutic activity (Sun et al., 2012; Hao et al., 2015; Rodrigues et al., 2015).

Finasteride (FSD), 17β-[N-(tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, is an orally active inhibitor of the intracellular enzyme 3-oxo-5α-steroid 4-dehydrogenase that is responsible for conversion of androgen testosterone into 5α-dihydrotestosterone (Tian et al., 1994). A decrease in the blood level of the later will result in a decrease in prostatic volume. FSD is considered a surgical alternative oral
drug suspension was ultrasonicated for 10 min under ice cooling condition using Sonics VCX 750, Sonics & Materials Inc. (Newtown, CT). Dried m-FSD were obtained after freeze drying for 48 h at −90 °C under 0.01 mbar pressure using alpha 1–2 LD plus, Christ lyophilizer (Osterode am Harz, Göttingen, Germany). For preparation of FSD nanoparticles (n-FSD); an alcoholic drug solution (100 mg/mL) was prepared and added dropwise into the same volume of 0.67% w/v PVA aqueous solution on a magnetic stirrer at 1000 rpm at a ratio of 0.154:10 alcoholic to PVA aqueous phase. The mixture was left on a magnetic stirrer at 1000 rpm until evaporation of methanol was completed. The aqueous drug dispersion obtained was homogenized at 17,660 rpm using UltraTurrax, IKA® T18 basic Homogenizer (IKA, Campinas, Brazil) for 10.584 min. Dried n-FSD were obtained following freeze drying as previously described.

**Characterization of the prepared micro and nanoparticles**

The obtained m-FSD and n-FSD were subjected to particle size and zeta potential measurement using Zetasizer of Microtrac Inc. (Montgomeryville, PA). Solubility enhancement of the developed particles was assessed after evaluation the solubility of the pure drug and the solubility of the prepared m-FSD and n-FSD in distilled water. Briefly, excess amount of each sample was placed in a screw cap glass vial containing 10 mL of distilled water and the vials were kept shaking at room temperature for 72 h in a thermostatically controlled shaking water bath (Model 1031; GFL Corporation, Burgwedel, Germany). Aliquots of each vial were withdrawn, filtered using Acrodisc® syringe filter of 0.45 μm, and analyzed for the drug concentration in the clear filtrate using HPLC (Ahmed & El-Say, 2016). The solubility enhancement was estimated using the following equation:

\[
SE = \frac{A - B}{A} \times 100
\]

where SE is the solubility enhancement, A is the aqueous solubility of the prepared m-FSD or n-FSD formulations and B is the aqueous solubility of the pure FSD.

**In vitro dissolution of the pure FSD powder and the prepared m-FSD and n-FSD was performed using United States Pharmacopeia (USP) dissolution test apparatus II paddle type, DT 700 LH device, Erweka GmbH DT 700 (Heusenstamm, Germany) at 37 °C for 2 h, with a stirring rate of 50 rpm, in 500 mL distilled water containing 0.05% sodium lauryl sulfate, to provide sink condition. Samples (n = 3) were withdrawn and analyzed for drug content using HPLC.

**Construction of FSD calibration curve in plasma and tissue homogenate**

Plasma and tissue homogenates samples spiked with FSD were prepared by adding known concentration of the drug to 2 mL of either blank plasma or tissue homogenates to reach a concentration range of 5–200 ng/mL for calibration analysis. The prepared samples were frozen at −80 °C and then subjected to freeze drying using alpha 1–2 LD plus, Christ lyophilizer.
The prepared plasma and tissue homogenates samples were subjected to NIR analysis using Thermo Fisher Scientific NICOLET iZ 10, Integrating Sphere Near-IR Spectrometer (Madison, WI). The spectra for pure FSD, freeze-dried drug free plasma and freeze-dried FSD plasma samples were recorded over the wave length range 4000–10,000 cm \(^{-1}\) against % transmittance to identify the characteristic NIR drug frequency region (finger print). The studied samples were measured without any sample preparation. The transmission spectra collected for each sample were the average of 36 scans and were visualized and chemometrically processed using the TQ Analyst software (tenth edition; Thermo Fisher Scientific).

For calculation of the drug concentration, partial least square (PLS) regression was used to relate the obtained spectroscopic data to the drug concentration. PLS is a factor which process all the data from a full spectrum and then uses only the relevant factors that are present in the spectral data (Merckle & Kovar, 1998). This factor is used to develop a calibration model based on the data of the calibration set which can then be used to expect the drug concentration from the spectra of the test set.

Selectivity was tested through assessment of the potential interference at the characteristic drug frequency region with endogenous components. Linearity of the method was studied for the samples used for construction of the calibration curve in plasma and tissue homogenate in the concentration range, 5–200 ng/mL where linear regression estimated the goodness-of-fit. Intra and interday precision and accuracy were evaluated by analysis of three replicates of plasma and tissue homogenate samples containing three different concentrations on the same and three separate days. For assessment of the method precision, the relative standard deviation was calculated according to the following equation:

\[
\text{Relative standard deviation} = \frac{\text{Calculated standard deviation}}{\text{mean observed concentration}} \times 100
\]

Method accuracy was calculated as the mean concentration found relative to the actual concentration.

Animals
Male Sprague Dawley rats (weight 150–175 g) were maintained in the pathogen-free area of the Pharmacology and Toxicology Department, Faculty of Pharmacy, King Abdulaziz University (Jeddah, KSA). Animals had access to food and water ad libitum. Animal experimental protocol was approved by the Ethical and Animal Care Committee at Faculty of Pharmacy, King Abdulaziz University.

Pharmacokinetics and tissue distribution of FSD after oral administration of different formulations
To determine the influence of different formulation on the plasma pharmacokinetics and tissue distribution of FSD, rats were orally given suspension of 0.4 mg/kg pure FSD (c-FSD), m-FSD or FSD nanoparticles (n-FSD) in CMC solution. Animals were anesthetized and blood samples were taken at different time points (0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h). Immediately afterward, animals were euthanized by cervical dislocation, and prostate, liver, spleen, kidney, lung and testis were harvested within 20 min and stored at \(-80^\circ\text{C}\) to be assayed. The collected plasma samples were frozen at \(-80^\circ\text{C}\) and subjected to freeze drying while, the tissue samples were homogenized in PBS (20% w/v) before they were subjected to freeze drying. Assayed for FSD content was achieved using Near IR method previously described in the above section.

Cell culture and cellular pharmacokinetics
To assess the ability of different FSD formulation to permeate cell membrane of prostate tissue, we measured the ability of FSD and different formulations to penetrate to the intracellular compartment of prostate cells. In brief, normal human prostate epithelial cells were generously gifted from Dr. Zakaria Abd Elmageed (College of Pharmacy, Texas A&M Health Science Center, Kingsville, TX), and maintained in RPMI-1640 media supplemented with 100 μg/ml streptomycin, 100 units/ml penicillin and 10% heat-inactivated fetal bovine serum in a humidified chamber at 37 °C supplied with 5% (v/v) CO₂.

For cellular pharmacokinetics assessment, 1 \(\times 10^6\) viable cells were seeded and left to attach for 24 h. Cells were exposed to suspension of the different formulations of FSD (10 μg/ml) and collected by trypsinization after 1, 3, 6, 24 and 48 h. Cells were washed twice with ice-cold PBS and then ruptured by sonication in hypotonic saline solution (1 ml) for 20 min. Ruptured cells were mixed with acetonitrile (1 ml), acetone (250 μl) and saturated ZnSO₄ solution (100 μl) centrifuged at 13,200 rpm for 10 min to remove debris. FSD in the supernatant was assayed using HPLC of Agilent 1200 series equipped with UV, diode array detector. Agilent C18 100 mm ×3.3 mm, 4.5 μm particle size analytical column (Agilent Technologies, Inc., Littelfall, CA) was used. An isotropic mobile phase consists of acetonitrile:15 mM phosphate buffer:tetrathydrofuran (42:55:3) v/v was delivered at a flow rate of 0.4 ml/min and the detector wave length was set at 220 nm. The HPLC method was reproduced except for slight modification to that previously published by Anutra et al. (2003).

Statistical analysis
Data are presented as mean ± standard error of mean (SEM). Analysis of variance (ANOVA) with LSD post hoc test was used for testing the significance using SPSS® for windows, version 17.0.0 (Chicago, IL). \(p < .05\) was taken as a cut off value for significance.

Results and discussion
The concept of particle size reduction, which is accompanied by increase in the particle surface area and drug solvation, is well-known to increase the drug dissolution rate as previously described by the famous Noyes–Whitney equation (Dokoumetzidis & Macheras, 2006). The technique is therefore
usually used to enhance the bioavailability of poorly soluble drugs (Sun et al., 2012). Several formulation and processing factors were studied for their effect on the development of m-FSD and n-FSD. PVA was selected as a stabilizer. It is a water soluble protective colloid that is adsorbed on the particle surface and facilitate formation of small size and stable particles during the size reduction process (Ahmed, 2016). The concentration of PVA was found to be critical since, insufficient PVA concentration will not provide adequate coverage of the particles, while at higher PVA concentration polymeric micelles will be formed that affect the thermal stability of the prepared particles (Wang et al., 2013). Other studied parameters such as the ratio of methanolic solution, homogenization speed and time of homogenization were also studied, and their optimum levels are presented in Table 1. Discussion about the effect of each factor and the optimum concentration were illustrated in our previously published work (Ahmed, 2016; Ahmed & El-Say, 2016).

Results of the characteristics for the prepared m-FSD and n-FSD are illustrated in Table 1. m-FSD and n-FSD of 930 and 645 nm, respectively were obtained. Zeta potential, which reflects the particles surface charges, was ~2.40 mV. Enhancement of the drug solubility following formulation of m-FSD and n-FSD was found to be 124 and 159.24%, respectively. In vitro dissolution revealed enhancement of the rate of drug dissolution from m-FSD and n-FSD by 2–2.5 times when compared with pure FSD powder (data not shown). Enhancement of the drug solubility and dissolution is directly related to size reduction, the effect which was significant in n-FSD when compared to m-FSD since the former possess smaller size than the later. Flakes like, non-spherical, short rods small plates were the morphology of the obtained microparticles as indicated by images of the scanning electron microscope (Ahmed & El-Say, 2016), while small homogenous spherical particles were noticed for the n-FSD (Ahmed 2016). Physicochemical characterization of the prepared particles revealed compatibility among ingredients as illustrated from the Fourier-transformed infrared and differential scanning calorimetry of the drug, PVA, physical mixture and the optimized formulation (Ahmed 2016). X-ray powder diffraction demonstrated crystalline state transformation from the crystalline state in the pure drug powder into the amorphous form in the optimized freeze-dried drug particles (Ahmed 2016).

FSD calibration curve in plasma and tissue homogenate using NIR spectroscopy

Recently, NIR spectroscopy technique has gained a great interest and a wide range of application within the pharmaceutical industry for testing of raw material, product quality control and process monitoring. This great interest is perhaps a direct consequence of the technique major advantages over other currently used analytical techniques (Siddiqui et al., 2017). Following analysis of the plasma and tissue homogenates samples spiked with FSD using NIR and calculation of the drug concentration from the spectra; selectivity, linearity, precision and accuracy of the method were calculated.

The characteristic FSD finger print region was detected between 9921 and 9924 cm⁻¹. Selectivity of the method was confirmed in which no potential interference at the characteristic drug frequency region with endogenous components was detected. The calculated R² value where found to be 0.9566. Intra and interday precision and accuracy were also confirmed. The relative standard deviation was found to be within 15% while, the accuracy was calculated and found in the range 85–115%. The limit of detection (LOQ) and limit of

Figure 1. Plasma pharmacokinetics of FSD and its formulations. Different formulations of FSD (c-FSD, m-FSD and n-FSD) were administered to rats (0.4 mg/ml), blood samples were taken from retro-orbital plexus at different time points and plasma concentrations of FSD (A), maximum FSD concentration (B) and plasma overall exposure to FSD (C) were plotted. Data are expressed as mean ± SEM; n = 3; (*) indicates significantly different from corresponding control at p < .05.
Quantification (LOD) were found to be 1 and 5 ng/ml, respectively.

**Pharmacokinetics and tissue distribution of FSD formulations**

After single oral administration of FSD (formulated and non-formulated) to normal rats, central compartment pharmacokinetics (plasma pharmacokinetics) and tissue distribution into target treatment tissue (prostate), nearby sex organ (testis), major reticuloendothelial/excretion organs (spleen, liver and kidney) and nonspecific random tissue (lung) were evaluated after different time points (Figures 2 and 3). Maximum plasma FSD concentration was achieved within 2 ± 0.7 h, 5.3 ± 0.5 h and 3.0 ± 1.1 h for c-FSD, m-FSD and n-FSD, respectively (Figure 1(a)). However, comparable C_{max} for c-FSD, m-FSD and n-FSD were observed (300.7 ± 14.6, 291.6 ± 6.4 and 317.1 ± 9.3 ng/ml, respectively) (Figure 1(b)). Similarly, comparable AUCs for c-FSD, m-FSD and n-FSD were also observed (3.9 ± 0.2, 4.2 ± 0.3 and 3.3 ± 0.5 μg.h/ml, respectively); which are indicative of similar overall systemic exposure to FSD (Figure 1(c)). Maximum FSD concentration

![Figure 2. Tissue distribution of FSD and its formulations. Different formulations of FSD (c-FSD, m-FSD and n-FSD) were administered to rats (0.4 mg/ml), tissue samples such as prostate (A), liver (B), spleen (C), kidney (D), lung (E) and testis (F) were surgically extracted immediately after euthanasia and concentrations of FSD within the selected organs were plotted against time. Data are expressed as mean ± SEM; n = 3; (*) indicates significantly different from corresponding control at p < .05.](image_url)
was achieved within prostate tissue after 6 ± 1.6 h and 5.2 ± 2.7 h for c-FSD and m-FSD, respectively. Interestingly, n-FSD managed to deposit FSD within prostate tissue as early as after 1.3 ± 0.2 h. However, comparable $C_{\text{max}}$ (159.6 ± 13.5, 207.6 ± 9.3 and 178.9 ± 8.7 ng/g tissue) (Figure 3(a)) and AUC's (2.5 ± 0.2, 2.6 ± 0.2 and 2.2 ± 0.1 μg h/g tissue) were noticed for c-FSD, m-FSD and n-FSD, respectively; which are indicative of similar overall prostate tissue exposure to FSD.

![Figure 3](image.png)

Figure 3. Tissue exposure parameters of FSD and its formulations. Different formulations of FSD (c-FSD, m-FSD and n-FSD) were administered to rats (0.4 mg/ml), tissue samples of prostate, liver, Spleen, Kidney, lung and testis were surgically extracted immediately after euthanasia and maximum concentrations ($C_{\text{max}}$) of FSD (A) and total tissue exposure (AUC) to FSD were plotted. Data are expressed as mean ± SEM; $n = 3$; (*) indicates significantly different from corresponding control at $p < .05$. 

T. A. AHMED AND A. M. AL-ABD
In previous studies, dihydrotestosterone (DHT) concentration within prostate tissue was taken to indirectly assess FSD effect rather than actual intra-prostatic FSD concentration (Wurzel et al., 2007). Similarly, liver tissues showed comparable exposure parameters after treatment with c-FSD, m-FSD and n-FSD. C\text{max}'s were 166.3 ± 21.3, 176 ± 2.9 and 198.3 ± 4.8 ng/g tissue; T\text{max}'s were 3.2 ± 0.6, 1.3 ± 0.3 h and 4.5 ± 1.3 h (Figure 3(b)); and AUC’s were 1.8 ± 0.1, 1.9 ± 0.2 and 2.7 ± 0.4 µg h/g tissue for c-FSD, m-FSD and n-FSD, respectively (Figure 2(b)). Intrahepatic FSD metabolism is crucial for its elimination, and relatively delayed hepatic T\text{max} for n-FSD might improve its circulation time and prolong its activity (Ishii et al., 1994).

With respect to spleen tissue, c-FSD and m-FSD showed non-significantly different C\text{max}'s of 154.1 ± 7.6 and 177.7 ± 8.1 ng/g tissue, at T\text{max}'s of 5.3 ± 1.2 h and 4.5 ± 1.1 h, respectively. Only n-FSD showed higher C\text{max} of 221.1 ± 10 ng/mg tissue at 22 ± 0.8 h (T\text{max}) (Figure 3(c)). This was significantly reflected as higher overall exposure of spleen tissue to FSD after n-FSD treatment (AUC = 2.8 ± 0.06 µg h/g tissue) and even higher after n-FSD treatment (AUC = 3.6 ± 0.2 µg h/g tissue) compared to c-FSD treatment (AUC = 2.1 ± 0.1 µg h/g tissue) (Figure 2(c)). Oral administration eliminates the influence of any reticuloendothelial system to the clearance of formulated drugs; as they must be dissolved to be absorbed (Zhang et al., 2008). Herein, FSD possess positive and beneficial influence to spleen-dependent erythropoietin secretion and activity (Barcelo et al., 1999).

Kidney is the major excretory organ for many drugs; intranephritic FSD concentration either reflects excretion or accumulation and nephropathy (Haque et al., 2017; Merkely et al., 2017). Fortunately, kidney tissues showed comparable exposure parameters after treatment with c-FSD, m-FSD and n-FSD. C\text{max}'s were 183.2 ± 19.9, 241.4 ± 19.4 and 214.8 ± 19.1 ng/g tissue (Figure 3(d)); T\text{max}'s were 3.3 ± 0.9, 5.2 ± 1.4 and 1.3 ± 0.1 h; and AUC’s were 2.4 ± 0.4, 2.8 ± 0.2 and 2.6 ± 0.1 µg h/g tissue for c-FSD, m-FSD and n-FSD, respectively (Figure 2(d)). FSD is not reported to undergo excessive renal clearance and kidney tissue does not possess FSD target enzyme and is not expected to be affected by FSD concentration (Steiner, 1996). Yet, renal tissue distribution of FSD might not be of high impact on either kidney or FSD itself.

Prostate and other male sex organs are sharing the same blood supply; drugs intended to target prostate such as FSD might additionally accumulate in other structurally adjacent or anatomically linked sex organ. It was reported that FSD might induce masculine-related side effects such as, erectile dysfunction (Zhang et al., 2012). Testis and testicular tissues are very sensitive to many drugs and to finasteride itself (Kolasa-Wolosiuk et al., 2015; Soni et al., 2017). Fortunately, FSD formulation did not influence its testicular maximum concentration (C\text{max}) or the overall testis exposure (AUC). C\text{max}'s were 192.8 ± 10.0, 208.7 ± 12.6 and 194.7 ± 20.4 ng/g tissue (Figure 3(f)); and AUC’s were 2.9 ± 0.1, 2.9 ± 0.5 and 2.8 ± 0.1 µg h/g tissue for c-FSD, m-FSD and n-FSD, respectively (Figure 2(f)).

Tissue distribution of FSD within lung was assessed as a representative of nonselective tissue distribution. To the best of our knowledge, no reports for the FSD accumulation within lung tissue (Steiner, 1996). Similarly, FSD formulation did not influence its maximum tissue concentration (C\text{max}) or the overall tissue exposure (AUC). C\text{max}'s were 167.0 ± 20.1, 184.1 ± 14.4 and 184.7 ± 7.9 ng/g tissue (Figure 3(e)); and AUC’s were 1.5 ± 0.1, 2.0 ± 0.3 and 1.9 ± 0.2 µg h/g tissue for c-FSD, m-FSD and n-FSD, respectively (Figure 2(e)).

**Cellular permeation of FSD formulations**

FSD is known to exert its action via inhibiting the intracellular enzyme (type II 5α-reductase). Yet, FSD intracellular permeation is crucial for its activity. Herein, we assessed the cellular permeation of FSD and its different formulation (m-FSD and n-FSD) within normal prostate epithelial cells

**Figure 4.** Cellular permeation of FSD and its formulations. Normal prostate epithelial cells (BPH cells) were exposed to 10 µg/ml different formulations of FSD (c-FSD, m-FSD and n-FSD), intracellular concentration of FSD were assessed after different time points (A), intracellular C\text{max} (B) and intracellular AUC (C) were plotted. Data are expressed as mean ± SEM; n = 3; (*) indicates significantly different from corresponding control at p < .05.
(PBH-1). Only, n-FSD significantly increased the intracellular FSD $C_{\text{max}}$ and at earlier $T_{\text{max}}$ (1.3 ± 0.1 ng/cell and 0.5 ± 0.01 h, respectively) compared to 0.9 ± 0.07 ng/cell and 4.2 ± 1.3 h for unformulated FSD. Unfortunately, m-FSD did not influence the intracellular $C_{\text{max}}$ of FSD nor its $T_{\text{max}}$ (1.2 ± 0.2 ng/cell and 5.1 ± 0.1 h, respectively) (Figure 4). It is well-recognized that permeation assessment for any proposed 5α-reductase inhibitor is crucial rather than only assessing cell free enzyme inhibition (Mathur et al., 2004). Cellular permeation mechanisms are diverse such as, passive transport, active transport, endocytosis and phagocytosis. For the vast majority of particulate formulations (such as m-FSD and n-FSD), phagocytosis is expected to the be the predominating route of permeation (Lam et al., 1993; Gratton et al., 2008).

Conclusions

In conclusion, nano-sized formulation of FSD significantly improved its cellular permeation. However, no significant changes in systemic pharmacokinetics (AUC and $C_{\text{max}}$) were noticed due to size reduction. On the other hand, intra-prosthetic accumulation was better for m-FSD rather than n-FSD and c-FSD; which could be explained by the higher reticulo-endothelial uptake for n-FSD by the spleen.

Acknowledgements

The authors gratefully acknowledge the DSR technical and financial support.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia, under grant no. [D-168-166-1437].

References

Ahmed T. (2016). Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation. Int J Nanomedicine 11:515–27.

Ahmed TA, El-Say KM. (2016). Transdermal film-loaded finasteride microplates to enhance drug skin permeation: two-step optimization study. Eur J Pharm Sci 88:246–56.

Anutra K, Kumsorn B, Rojanasthien N. (2003). Bioequivalence study of generic finasteride in healthy male volunteers. Chiang Mai Med Bull 42:131–7.

Barcelo AC, Olivera MI, Bozzini C, et al. (1999). Androgens and erythropoiesis. Induction of erythropoietin-hypersecretory state and effect of finasteride on erythropoietin secretion. Comp Haematol Inv 9:1–6.

Blagden N, de Matas M, Gavan PT, Yong P. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 59:617–30.

Dokoumetzidis A, Macheras P. (2006). A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 321:1–11.

Gratton SEA, Ropp PA, Pohlhaus PD, et al. (2008). The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105:11613–8.

Hao J, Gao Y, Zhao J, et al. (2015). Preparation and optimization of resveratrol nanosuspensions by antioxidant precipitation using box-behenken design. AAPS PharmSciTech 16:118–28.

Haque A, Ishii Y, Akasaka Y, et al. (2017). Administration of colistin sulfate in endotoxic model at slow and sustained fashion may reverse shock without causing nephrotoxicity in its optimal concentration. J Glob Antimicrob Resist 11:40–4.

Ishii Y, Mukoyama H, Ohtawa M. (1994). In vitro biotransformation of finasteride in rat hepatic microsomes. Isolation and characterization of metabolites. Drug Metab Dispos 22:79–84.

Jinno J, Kamada N, Miyake M, et al. (2006). Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 111:56–64.

Junghanns JUAH, Müller RH. (2008). Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 3:295–309.

Kolasa-Wolsiuk A, Misiakievicz-Has K, Baranowska-Bosiacka I, et al. (2015). Androgen levels and apoptosis in the testis during postnatal development of finasteride-treated male rat offspring. Folia Histochim Cytobiol 53:236–48.

Lam KH, Schakenraad JM, Esselbrugge H, et al. (1993). The effect of phagocytosis of poly (l-lactic acid) fragments on cellular morphology and viability. J Biomed Mater Res Part A 27:1569–77.

Mathur S, Picard F, Dossou U, et al. (2004). Evaluation of cell permeation of a potent 5α-reductase inhibitor using MALDI-TOF MS. J Enzyme Inhib Med Chem 19:425–9.

Maureen Dale M, Rang H. Rang’s pharmacology. 7th ed. New York: Elsevier/Churchill Livingstone; 2012.

Merkle P, Kovar K. (1998). Assay of effervescent tablets by near-infrared spectroscopy in transmittance and reflectance mode: acetylsalicylic acid in mono and combination formulations. J Pharm Biomed Anal 17:365–74.

Merkely B, Dósa E, Neuwelt EA, et al. (2017). Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto-and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency. Fluids Barriers CNS. BioMed Central 14:26.

Monti D, Tampucci S, Burglassi S, et al. (2014). Topical formulations containing finasteride. Part I: in vitro permeation/permeability study and in vivo pharmacokinetics in hairless rat. J Pharm Sci 103:2307–14.

Pande WV, Abhalde VN. (2013). Nanocrystal technology: a particle engineering formulation strategy for the poorly water soluble drugs. Int J Pharm 453:126–41.

Prahalada SR, Keenan KP, Hertzog PR, et al. (1994). Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor. Urology 43:680–5.

Rodrigues S, Cordeiro C, Seijo B, et al. (2015). Hybrid nanosystems based on natural polymers as protein carriers for respiratory delivery: stability and toxicological evaluation. Carbohydr Polym 123:369–80.

Rogers TL, Johnston KP, Williams RO. (2001). Solution-based particle formulation on natural polymers as protein carriers for respiratory delivery: information of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies. Drug Dev Ind Pharm 27:1003–30.

Soni KK, Shin YS, Choi BR, Karna KK, Kim HK, Lee SW, et al. (2017). Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway. J Biomed Mater Res Part A 27:1569–77.

Siddiqui MR, AlOthman ZA, Rahman N. (2017). Analytical techniques in pharmaceutical analysis: a review. Arab J Chem 10:S1490–S21.

Soni KK, Shin YS, Choi BR, Karna KK, Kim HK, Lee SW, et al. (2017). Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway. Drug Des Devel Ther 11:2969.

Steiner JF. (1996). Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30:16–27.

Sun J, Wang F, Sui Y, et al. (2012). Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals. Int J Nanomedicine 7:5733–44.

Sutrathdar KB, Khatun S, Luna IP. (2013). Increasing possibilities of nanosuspension. J Nanotechnol 2013:1–12.
Tampucci S, Burgalassi S, Chetoni P, et al. (2014). Topical formulations containing finasteride. Part II: determination of finasteride penetration into hair follicles using the differential stripping technique. J Pharm Sci 103:2323–9.

Tian G, Stuart JD, Moss ML, et al. (1994). 17 Beta-((N-tert-butylcarbamoyl)-4-aza-S alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid S alpha-reductase 1. Biochemistry 33:2291–6.

Van Eerdenbrugh B, Van den Mooter G, Augustijns P. (2008). Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 364:64–75.

Wang H, Li Q, Reyes S, et al. (2013). Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity. Malar Res Treat 2013:1–10.

Wang Y, Zheng Y, Zhang L, et al. (2013). Stability of nanosuspensions in drug delivery. J Control Release 172:1126–41.

Willmann S, Thelen K, Becker C, et al. (2010). Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 76:83–94.

Wurzel R, Ray P, Major-Walker K, et al. (2007). The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 10:149–54.

Zhang L, Gu FX, Chan JM, et al. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761–9.

Zhang M, Wu W, Zhang C, et al. (2012). Effects of oral finasteride on erectile function in a rat model. J Sex Med 9:1328–36.